作者: David S. Liebeskind , Scott E. Kasner
DOI: 10.2165/00023210-200115030-00001
关键词:
摘要: Neuroprotective therapies for acute ischaemic stroke have yet to be realised despite the determined efforts of basic science and clinical investigators. Progressive elucidation complex pathophysiology involved in cascade has led development numerous candidate interventions. Preliminary efficacy animal models repeatedly resulted frustration after extensive testing. Failure translation results from humans implicates potential limitations current drug process. Reflection on prior studies suggests possible flaws at several stages. Incorporation standardised guidelines preclinical testing putative neuroprotective modification trial design, methodology reporting may improve chances success. The future neuroprotection remains bright spite previous disappointments.